| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/09/2006 | WO2005089449A3 Methods for treating alcoholism |
| 03/09/2006 | WO2005087238A3 Method for stimulating the immune, inflammatory or neuroprotective response |
| 03/09/2006 | WO2005086971A3 Anti-metastatic ability of mibefradil and gadolinium |
| 03/09/2006 | WO2005063239A9 3-(4-piperidine-1ylmethyl-phenyl)-propion acid-phenylamide-derivatives and related compounds used in the form of mch antagonists (melanine concentrating hormone) for treating eating disorders |
| 03/09/2006 | WO2005058314A3 Methods for reducing the effects of stress on skin condition |
| 03/09/2006 | WO2005054258A3 New class of gamma delta t cells activators and use thereof |
| 03/09/2006 | WO2005051368A3 Phosphodiesterase v inhibitor formulations |
| 03/09/2006 | WO2005040228A3 Disintegratable films for diagnostic devices |
| 03/09/2006 | WO2005027872A3 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof |
| 03/09/2006 | WO2005018541A3 Cox-2 inhibitor and serotonin modulator for treating cns damage |
| 03/09/2006 | WO2005014572A8 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 03/09/2006 | WO2004108077A3 Method of mitigating the adverse effects of il-2 |
| 03/09/2006 | WO2004089296A3 Improved inhibitors for the soluble epoxide hydrolase |
| 03/09/2006 | WO2003103598A3 Amidine derivatives for treating amyloidosis |
| 03/09/2006 | WO2003083068A3 Compounds and methods |
| 03/09/2006 | US20060053516 Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS |
| 03/09/2006 | US20060052610 Piperidine derivatives and process for their production |
| 03/09/2006 | US20060052605 1,4-disubstituted piperazine compounds; for example 2-{4-[2-(acetylamino)-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3-phenylphenyl)acetamide; cardiovascular diseases such as arrhythmias, intermittent claudication, angina, congestive heart disease, diabetes, and myocardial infarction |
| 03/09/2006 | US20060052603 Process for preparing substituted phenoxy-acetic acids from phenols |
| 03/09/2006 | US20060052595 Heterocyclic compounds as ccr5 antagonists |
| 03/09/2006 | US20060052594 New corticosteroids |
| 03/09/2006 | US20060052491 Synergistic uv absorber combination |
| 03/09/2006 | US20060052461 Antitumor agents; 2-Methoxy-17a-oxo-17a-homoestra-1,3,5(10)-trien-3-ol 1; estrogen-dependent diseases |
| 03/09/2006 | US20060052460 Latent reactive blood compatible agents |
| 03/09/2006 | US20060052459 Antifungal medicaments comprising arylamidine derivatives |
| 03/09/2006 | US20060052458 Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia |
| 03/09/2006 | US20060052457 Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| 03/09/2006 | US20060052456 Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells |
| 03/09/2006 | US20060052455 Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction |
| 03/09/2006 | US20060052454 Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders |
| 03/09/2006 | US20060052453 Agent for treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient |
| 03/09/2006 | US20060052452 Phenolic antiseptic compositions and methods of use |
| 03/09/2006 | US20060052451 Method |
| 03/09/2006 | US20060052450 Use of l-carnitine for the treatment of cardiovascular diseases |
| 03/09/2006 | US20060052449 4'-(2-phenoxy-ethylsulfanylmethyl)-biphenyl-3-carboxylic acid (3-dimethylamino-propyl)-amide oxalate; inhibiting release of the melanin concentrating hormone; treating Type II Diabetes, obesity |
| 03/09/2006 | US20060052448 Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production. |
| 03/09/2006 | US20060052447 Novel substituted arylhexadienoic acids and esters thereof which can be used for the treatment and prevention of diabetes, dyslipidaemia and atherosclerosis, pharmaceutical compositios comprising them and processes for the preparation of them |
| 03/09/2006 | US20060052446 Fatty acid-containing compositions and methods for the treatment of cytokine mediated disorders |
| 03/09/2006 | US20060052445 Diarylsulfones as 5-HT2A antagonists |
| 03/09/2006 | US20060052441 Dosage form of polysaccharides, especially cocoa extracts, containing procyanidine units an additional nitric oxide modulating agent; dietary supplements; pet foods |
| 03/09/2006 | US20060052440 Medicinal composition for treating sudden deafness |
| 03/09/2006 | US20060052439 Salvinorin derivatives and uses thereof |
| 03/09/2006 | US20060052438 Bioactive compounds and methods of uses thereof |
| 03/09/2006 | US20060052437 Combination of an hmg-coa reductase inhibitor and a nitrate ester |
| 03/09/2006 | US20060052436 Pyrroloterpenes and use of the same as antimicrobial and anticancer agents |
| 03/09/2006 | US20060052435 Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction |
| 03/09/2006 | US20060052434 Pyrrolizine compounds useful as anti-inflammatory agents |
| 03/09/2006 | US20060052433 Compound |
| 03/09/2006 | US20060052432 Pharmaceutical compositions with improved dissolution |
| 03/09/2006 | US20060052431 5-Hydroxy indazole derivatives for treating glaucoma |
| 03/09/2006 | US20060052430 Antihistamines for increased tolerance to extreme heat |
| 03/09/2006 | US20060052429 Oromucosal formulation and process for preparing the same |
| 03/09/2006 | US20060052428 Neurological functions |
| 03/09/2006 | US20060052427 Pulmonary Emphysema; Chronic Bronchitis; bis-(1H-tetrazol-5-yl)phenylbenzamide derivative called andolast; potent inhibitory effect on IL-4 dependent IgE synthesis; decreases both antibody-mediated and cell-mediated inflammatory responses; good ability to activate calcium (Ca2+)-dependent K+ channels |
| 03/09/2006 | US20060052426 Acylaminothiazole derivatives, their preparation and their therapeutic use |
| 03/09/2006 | US20060052425 Method for modulating microbial quorum sensing |
| 03/09/2006 | US20060052424 Lactacystin analogs |
| 03/09/2006 | US20060052423 Peptide deformylase inhibitors |
| 03/09/2006 | US20060052421 Conjugation agent |
| 03/09/2006 | US20060052420 Thiazolo-naphthyl acids |
| 03/09/2006 | US20060052419 Use of pyridly amides as inhibitors of angiogenesis |
| 03/09/2006 | US20060052418 Viral polymerase inhibitors |
| 03/09/2006 | US20060052417 N3-((1-(2-Oxo-2-(phenylamino)ethyl)-4-piperidyl)methyl)- 1-(1-methylethyl)-1H-indazole-3-carboxamide; antiarthritic agents; rheumatic diseases; osteoarthritis; fibromyaleia;anticarcinogenic agents, pain; neuropathic pain; immunoincompetance; trauma; antiischemic agents; multiple sclerosis |
| 03/09/2006 | US20060052416 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 03/09/2006 | US20060052415 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
| 03/09/2006 | US20060052414 Compositions and methods for treating or preventing Hepadnaviridae infection |
| 03/09/2006 | US20060052413 Novel piperidine derivatives as modulators of chemokine receptor ccr5 |
| 03/09/2006 | US20060052412 2-(2-oxa-3-azabicyclo[2.2.2]oct-5-en-3-yl)-6-amino-9-methyl-1-deazapurine; antiinflammatory, neuroleptic agent, antiallergens, neuroprotectant and antidepressant, cognition activator; improved bioavailability, without a ribose moiety; prodrugs with primary or secondary amino or hydroxy groups |
| 03/09/2006 | US20060052411 Immunosuppressants, analgesics, antiinflammatory agents |
| 03/09/2006 | US20060052410 3,9-Dimethoxy-6H-chromeno[4,3-b]quinolin-7-ol; selective estrogen receptor beta modulators; diseases mediated by an estrogen deficiency or excess: osteoporosis, Crohn's disease, ulcerative proctitis, colitis, estrogen dependent cancers, hypercholesteremia, atherosclerosis, Alzheimer's disease |
| 03/09/2006 | US20060052409 Therapeutic or preventive agent for nausea/vomiting |
| 03/09/2006 | US20060052408 Cyclopropyl compounds as ccr5 antagonists |
| 03/09/2006 | US20060052407 crystal of a non-solvate of (3R)-1-butyl-2,5-dioxo-3-[(1R)-1-hydroxy-1-cyclohexylmethyl]-9-[4-(4-carboxyphenyloxy)phenylmethyl]-1,4,9-triazaspiro[5.5]undecane hydrochloride; chemokine antagonist |
| 03/09/2006 | US20060052406 Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor |
| 03/09/2006 | US20060052405 Hair loss prevention |
| 03/09/2006 | US20060052404 Pharmaceutical formulations comprising substituted xanthine compounds |
| 03/09/2006 | US20060052403 Novel adenine compound and use thereof |
| 03/09/2006 | US20060052402 Method of female sexual enhancement |
| 03/09/2006 | US20060052401 Method of female sexual enhancement |
| 03/09/2006 | US20060052400 Immunosuppressants; respiratory system disorders; asthma; chronic obstructive pulmonary disease |
| 03/09/2006 | US20060052399 Oxazolidinone derivatives as antibacterial agents |
| 03/09/2006 | US20060052398 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 03/09/2006 | US20060052397 Compounds for trearment of cardiovascular disorders and hypotensive agents |
| 03/09/2006 | US20060052396 Arylamines for the treatment of conditions associated with gsk-3 |
| 03/09/2006 | US20060052395 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; hydrates mucosal surfaces; are absorbed less rapidly, thus have a prolonged pharmacodynamic half-life; skin and respiratory disorders, vision deffects |
| 03/09/2006 | US20060052394 N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-(4-{4-[3-(1H-tetrazol-5-yl)propoxy]phenyl}butyl)guanidine hydrochloride; hydrates mucosal surfaces; are absorbed less rapidly, thus have a prolonged pharmacodynamic half-life; skin and respiratory disorders, vision deffects |
| 03/09/2006 | US20060052393 Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase |
| 03/09/2006 | US20060052392 Isoindoline derivative |
| 03/09/2006 | US20060052391 Administration of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one (flibanserin) |
| 03/09/2006 | US20060052390 Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition |
| 03/09/2006 | US20060052389 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| 03/09/2006 | US20060052388 Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
| 03/09/2006 | US20060052387 Organic compounds |
| 03/09/2006 | US20060052386 Sigma ligands for neuronal regeneration and functional recovery |
| 03/09/2006 | US20060052385 For therapy of neurological disorder |
| 03/09/2006 | US20060052384 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia |
| 03/09/2006 | US20060052383 New dihydropteridione derivatives, process for their manufacture and their use as medicament |
| 03/09/2006 | US20060052382 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 03/09/2006 | US20060052381 Solubilized topoisomerase poisons |
| 03/09/2006 | US20060052380 Novel compounds |